Windlas Biotech Limited share price

Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules. In addition, the company offers generic drugs for respiratory, anti-diabetic, gastroenterology, cardiovascular and multivitam…Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNSE: WINDLASISIN INE0H5O01029

16 Oct 2026, 3:29 PM IST₹917.40▼ 6.10 (0.66%)

Market Cap₹ 1,893 Cr.
Current Price₹ 917.40
High / Low₹ 1,182 / 697
Stock P/E29.3
Book Value₹ 275
Dividend Yield0.68 %
ROCE15.7 %
ROE12.20 %
Face Value₹ 5.0

More figures (10)

EPS (TTM)₹ 31.26
Price / Book3.33
OPM8.3 %
Debt / Equity0.06
Sales growth (3Y)20.8 %
Profit growth (3Y)16.0 %
Promoter holding66.2 %
EV / EBITDA16.2
Beta0.26
All-time high₹ 1,198

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
WINDLAS	-14.66%	+7.90%	+5.35%	+15.39%	-0.47%	+36.31%	+21.96%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Windlas Biotech Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹1,893 crore.
It trades at 29.3 times its last 12 months' earnings and 3.3 times book value.
Revenue grew 20.8% a year over the last 3 years, profit 16.0% a year.
Return on equity was 12.2% and return on capital employed 15.7% in the latest year.
Debt was 0.06 times shareholders' equity.
The share price is 22.4% below its 52-week high and down 0.5% over one year.
Promoters and insiders hold about 66.2%; institutions about 7.2%.

Pros

Company is almost debt-free (debt is 0.06 times equity).
Sales have grown 20.8% a year over the last 3 years.
Promoters hold a large stake of 63.31%.

Cons

No standout weaknesses in the reported figures.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Windlas Biotech Limited

Employees: 1,385
Head office: Dehradun

HealthcareDrug Manufacturers - Specialty & Generic

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Windlas Biotech	917.40	29.3	1,893	0.68	16	-1.79	238	17.66	15.7	12.2	3.33	8.3	0.06	66.22	904	20.8
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,835	54.57	9.1	27.1	18.39	25.0	1.79	63.18	13,753	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
7.	Cipla	1,325.10	31.8	1,07,051	0.98	789	-35.42	7,077	7.26	14.9	11.8	3.11	17.5	0.02	31.13	27,712	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
10.	Mankind Pharma	2,275.50	46.0	93,988	0.00	568	35.00	4,031	30.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
	Median: 30 Co.	1,712.85	34.3	44,046	0.34	679	8.79	5,956	18.81	15.3	16.5	4.96	19.1	0.21	55.20	20,499	13.5

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	141	145	153	162	171	175	187	195	203	210	222	233	238
YOY Sales Growth %	15.21%	20.72%	15.02%	35.51%	21.73%	20.97%	22.49%	20.22%	18.34%	19.95%	18.93%	19.53%	17.66%
	124	128	134	142	149	154	164	170	177	184	194	209	213
Material Cost %	63%	63%	63%	63%	63%	62%	62%	62%	62%	62%	62%	62%	62%
Employee Cost %	13%	14%	14%	14%	13%	16%	17%	16%	16%	15%	16%	18%	17%
Other Expenses %	12%	11%	11%	11%	11%	10%	9%	9%	10%	10%	9%	10%	10%
Operating Profit	16	17	19	20	22	21	23	25	26	27	29	24	25
OPM %	12%	12%	12%	13%	13%	12%	12%	13%	13%	13%	13%	10%	11%
Other Income	2	3	3	3	4	4	5	4	5	5	4	5	4
Interest	0	0	0	0	0	0	1	1	1	1	1	1	1
Depreciation	4	3	3	3	4	6	7	7	8	7	8	8	8
Profit before tax	15	16	18	20	23	18	20	20	21	23	24	20	20
	24%	26%	23%	24%	25%	26%	23%	23%	22%	24%	25%	25%	21%
Current tax	4	4	4	4	5	5	5	4	5	6	6	4	5
Deferred tax	-1	0	-0	0	1	0	-1	1	-0	0	-0	1	-1
	11	12	14	15	17	13	16	16	16	18	18	15	16
Profit to shareholders				15
YOY Profit Growth %	-22.61%	23.11%	15.06%	64.32%	48.49%	11.72%	11.60%	3.17%	-4.19%	31.05%	13.68%	-3.69%	-1.79%
EPS in Rs	5.37	5.79	6.75	7.26	8.17	6.47	7.49	7.45	7.77	8.43	8.48	7.12	7.58
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	145	153	162	171	175	187	195	203	210	222	233	238	248
YOY Sales Growth %		15.02%	35.51%	21.73%	20.97%	22.49%	20.22%	18.34%	19.95%	18.93%	19.53%	17.66%	18.09%
	128	134	142	149	154	164	170	177	184	194	209	213	221
Material Cost %	63%	63%	63%	63%	62%	62%	62%	62%	62%	62%	62%	62%	62%
Employee Cost %	14%	14%	14%	13%	16%	17%	16%	16%	15%	16%	18%	17%	18%
Other Expenses %	11%	11%	11%	11%	10%	9%	9%	10%	10%	9%	10%	10%	10%
Operating Profit	17	19	20	22	21	23	25	26	27	29	24	25	27
OPM %	12%	12%	13%	13%	12%	12%	13%	13%	13%	13%	10%	11%	11%
Other Income	3	3	3	4	4	5	4	5	5	4	5	4	5
Interest	0	0	0	0	0	1	1	1	1	1	1	1	2
Depreciation	3	3	3	4	6	7	7	8	7	8	8	8	7
Profit before tax	16	18	20	23	18	20	20	21	23	24	20	20	23
	26%	23%	24%	25%	26%	23%	24%	22%	24%	25%	25%	21%	23%
Current tax	4	4	4	5	5	5	4	5	6	6	4	5	6
Deferred tax	0	-0	0	1	0	-1	1	-0	0	-0	1	-1	-1
	12	14	15	17	13	16	15	16	18	18	15	16	18
YOY Profit Growth %		14.92%	64.32%	48.05%	11.71%	11.60%	0.85%	-3.92%	31.06%	13.68%	-1.79%	-1.65%	-0.07%
EPS in Rs	5.79	6.75	7.26	8.15	6.47	7.49	7.29	7.77	8.43	8.48	7.09	7.60	8.46
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	466	513	631	760	904
YOY Sales Growth %		10.12%	22.97%	20.43%	18.98%
	414	453	553	666	799
Material Cost %	65%	63%	63%	62%	62%
Employee Cost %	14%	14%	14%	16%	17%
Other Expenses %	10%	11%	11%	9%	10%
Operating Profit	52	60	78	94	105
OPM %	11%	12%	12%	12%	12%
Other Income	7	10	13	18	18
Interest	1	1	1	4	5
Depreciation	12	12	13	28	31
Profit before tax	46	57	77	80	87
	16%	25%	25%	24%	24%
Current tax	10	14	17	18	21
Deferred tax	-3	0	2	0	-0
	38	43	58	61	66
Profit to shareholders	38
YOY Profit Growth %		11.91%	36.51%	4.82%	8.95%
EPS in Rs	18.80	19.70	27.97	29.19	31.60
Dividend Payout %		18%			18%

Compounded Sales Growth

3 Years:: 21%

Compounded Profit Growth

3 Years:: 16%

Stock Price CAGR

5 Years:: 22%
3 Years:: 36%
1 Year:: 0%

Return on Equity

4 Years:: 12%
Last Year:: 12%

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	466	513	631	760	904	942
YOY Sales Growth %		10.12%	22.97%	20.43%	18.98%
	413	453	553	666	799	837
Material Cost %	65%	63%	63%	62%	62%	62%
Employee Cost %	14%	14%	14%	16%	17%	17%
Other Expenses %	10%	11%	11%	9%	10%	10%
Operating Profit	53	60	78	94	105	105
OPM %	11%	12%	12%	12%	12%	11%
Other Income	7	10	13	18	18	18
Interest	1	1	1	4	5	5
Depreciation	12	12	13	28	31	31
Profit before tax	46	57	77	79	87	87
	16%	25%	25%	24%	24%	23%
Current tax	10	14	17	18	21
Deferred tax	-3	0	2	0	-0
	39	43	58	61	66	66
YOY Profit Growth %		10.59%	36.35%	4.31%	9.54%
EPS in Rs	18.81	19.71	27.95	29.03	31.59	31.63
Dividend Payout %		18%	14%	19%	18%

Compounded Sales Growth

3 Years:: 21%
TTM:: 19%

Compounded Profit Growth

3 Years:: 16%
TTM:: 2%

Stock Price CAGR

5 Years:: 22%
3 Years:: 36%
1 Year:: 0%

Return on Equity

4 Years:: 12%
Last Year:: 12%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	10	10	10	11
Reserves	392	440	495	570
	5	4	33	35
Long term borrowings	0
Short term borrowings	0	0	27	30
	122	173	222	291
Trade payables	88	132	178	238
Current liabilities	121	172	249	321
Total Liabilities	529	626	760	907
	161	185	224	267
Gross block	243	277	342	415
Accumulated depreciation	82	92	119	148
Goodwill & intangibles	1	4	7	7
CWIP	53	11	5	57
	315	431	532	583
Inventories	75	62	81	62
Trade receivables	117	136	167	227
Cash & equivalents	4	5	0	1
Current assets	354	431	525	627
Total Assets	529	626	760	907

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	61	109	68	105
Profit for the year	43	58	61	66
Working capital changes	6	44	-9	-4
Direct taxes paid	-10	-19	-21	-15
	-14	-92	-74	-92
Fixed assets purchased	-71	-38	-52	-68
Fixed assets sold	1	0	0
Investments purchased			-50	-47
Investments sold			26	21
	-44	-15	1	-13
Repayment of borrowings	-0	-0
Interest paid	-1	-1	-4	-5
Dividends paid	-8	-8	-11	-12
Net Cash Flow	3	2	-5	0
Free Cash Flow	-10	71	16	37

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	10.6%	13.7%	12.8%	12.2%
ROCE	—	14.2%	17.2%	16.5%	15.7%
Operating margin	—	9.4%	10.3%	8.8%	8.3%
Net margin	—	8.3%	9.3%	8.1%	7.4%
Debt / equity	—	0.01	0.01	0.06	0.06
Current ratio	—	2.92	2.51	2.11	1.95
Debtor days	—	84	79	81	92
Inventory days	—	84	57	63	40
Days payable	—	98	121	138	156
Cash conversion cycle	—	70	15	6	-24
Working capital days	—	166	151	133	124

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 63.31%
FIIs 2.04%
DIIs 9.84%
Public 24.80%

%	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	62.82%	62.82%	62.82%	62.51%	62.51%	62.51%	62.34%	62.34%	61.99%	61.99%	61.90%	63.31%
	0.80%	1.35%	1.18%	1.59%	2.00%	1.55%	1.52%	1.44%	1.11%	0.93%	0.60%	2.04%
Foreign portfolio investors (Cat. I)	0.78%	1.35%	1.18%	1.24%	1.33%	1.08%	0.80%	0.55%	0.53%	0.89%	0.56%	1.65%
Foreign portfolio investors (Cat. II)	0.02%			0.35%	0.67%	0.47%	0.72%	0.89%	0.58%	0.04%	0.04%	0.39%
	11.53%	11.71%	11.82%	10.35%	9.58%	10.26%	10.89%	11.21%	11.43%	11.44%	11.81%	9.84%
Mutual funds	10.43%	10.40%	10.37%	8.70%	7.57%	7.11%	6.70%	6.80%	6.39%	6.63%	7.08%	5.76%
Banks	0.04%	0.04%
Alternative investment funds	1.05%	1.27%	1.45%	1.65%	2.01%	3.15%	4.19%	4.42%	5.05%	4.81%	4.72%	4.08%
	24.85%	24.12%	24.19%	25.55%	25.91%	25.68%	25.25%	25.01%	25.47%	25.64%	25.70%	24.80%
Retail (up to ₹2 lakh)	20.62%	19.77%	19.84%	20.02%	20.65%	20.40%	19.39%	19.19%	19.35%	19.73%	19.48%	18.97%
HNIs (above ₹2 lakh)	1.01%	1.44%	1.35%	1.74%	1.16%	1.14%	1.97%	1.68%	1.95%	1.56%	1.76%	1.47%
NRIs	0.92%	0.83%	0.99%	1.13%	1.10%	1.12%	1.00%	1.03%	1.12%	1.18%	1.37%	1.32%
Bodies corporate	1.07%	0.82%	1.08%	1.59%	1.78%	1.86%	1.82%	1.89%	1.60%	1.39%	1.28%	1.35%
No. of Shareholders	68,798	61,900	51,277	45,824	45,706	46,590	46,383	45,887	45,433	45,461	44,769	44,996

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding Windlas Biotech

No single fund or institution holds more than 1%.

As named in the shareholding pattern for Jun 2026 filed with NSE; mutual funds together hold 5.76% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 16 Jul 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Windlas Biotech Limited

What is the share price of Windlas Biotech Limited today?

Windlas Biotech Limited (WINDLAS) last traded at ₹917.40 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.

What is the market cap of Windlas Biotech Limited?

About ₹1,893 crore at the latest price.

What is the P/E ratio of Windlas Biotech Limited?

About 29.3 times its earnings over the last 12 months.

Is Windlas Biotech Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Windlas Biotech Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Windlas Biotech Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Windlas Biotech Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Mutual funds & institutions holding Windlas Biotech

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Windlas Biotech Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next